08:27 AM EDT, 07/21/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday it has submitted a new drug application to the US Food and Drug Administration seeking the first approval of icotrokinra, which is intended for the treatment of adults and pediatric patients aged 12 years and older with moderate to severe plaque psoriasis.

The application included data from four phase 3 studies conducted as part of the company's ICONIC clinical development program.

Based on the data, treatment with icotrokinra met all primary and co-primary endpoints across the development program among adults and pediatric patients aged 12 years and older with moderate-to-severe plaque psoriasis, demonstrating significant skin clearance and a favorable safety profile in a once-daily pill, the company said.